Page last updated: 2024-10-21

1,3-dipropyl-8-cyclopentylxanthine and Glioblastoma

1,3-dipropyl-8-cyclopentylxanthine has been researched along with Glioblastoma in 1 studies

DPCPX : An oxopurine that is 7H-xanthine substituted at positions 1 and 3 by propyl groups and at position 8 by a cyclohexyl group.

Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Taliani, S1
La Motta, C1
Mugnaini, L1
Simorini, F1
Salerno, S1
Marini, AM1
Da Settimo, F1
Cosconati, S1
Cosimelli, B1
Greco, G1
Limongelli, V1
Marinelli, L1
Novellino, E1
Ciampi, O1
Daniele, S1
Trincavelli, ML1
Martini, C1

Other Studies

1 other study available for 1,3-dipropyl-8-cyclopentylxanthine and Glioblastoma

ArticleYear
Novel N2-substituted pyrazolo[3,4-d]pyrimidine adenosine A3 receptor antagonists: inhibition of A3-mediated human glioblastoma cell proliferation.
    Journal of medicinal chemistry, 2010, May-27, Volume: 53, Issue:10

    Topics: Adenosine A3 Receptor Agonists; Adenosine A3 Receptor Antagonists; Animals; Antineoplastic Agents; B

2010